Quest Diagnostics has appointed Stephen Rusckowski as the chairman of its board of directors. Rusckowski succeeds Daniel Stanzione, who will be staying on as lead independent director. Rusckowski joined Quest in 2012 and continues to serve as president and CEO.
In a filing with the US Securities and Exchange Commission this week, Thermo Fisher Scientific announced that Peter Wilver will retire effective March 31, 2017. Wilver became an executive officer of the company in 2003 and is currently serving as executive vice president and chief administrative officer.
John McChesney, Tali Mackay, David Taylor, and Gregory Tsongalis
Theranos has appointed John McChesney, Tali Mackay, David Taylor, and Gregory Tsongalis to executive positions. McChesney has been named senior VP of operations. He previously served at Medtronic, Thermo Fisher Scientific, and GenapSys. Mackay has been named senior VP of corporate communications and investor relations. She previously worked at Genentech, Baxter, and various global public relations firms. Taylor has been promoted to general counsel. He joined Theranos as senior litigation counsel in May. Tsongalis has been appointed to the firm's Scientific and Medical Advisory Board. He has served on science and medical advisory boards at AltheaDx, Gentura Dx-USA, and Physicians Choice Laboratory Services.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.